Detailed price information for Aptevo Therapeutics Inc (APVO-Q) from The Globe and Mail including charting and trades.

Inc. (Market cap: $34.46M) has reported its financial performance for the fourth quarter of 2023, highlighting a steady cash flow and strategic advancements in its clinical pipeline. According to ...

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Anti-KIR blocking antibodies has led to important therapeutic implications in NK cell immunotherapy ... mediated killing of HLA-matched acute myeloid leukemia blasts in vitro and in vivo.

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medicalconditions. The company currently has a pipeline focusing on acute organ traumas,vascular ...